MIRATI THERAPEUTICS INC (MRTX) Stock Analyst Ratings
USA - NASDAQ:MRTX - US60468T1051 - Common Stock
58.7 USD
-0.1 (-0.17%)
58.99 USD
+0.29 (+0.49%)
ChartMill assigns a Buy % Consensus number of 69% to MRTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 62.42. This target is 6.34% above the current price.
MRTX was analyzed by 22 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about MRTX.
In the previous month the buy percentage consensus was at a similar level.
MRTX was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-12-20 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-11-07 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2023-11-07 | Stifel | Downgrade | Buy -> Hold |
| 2023-10-10 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-10-09 | ScotiaBank | Upgrade | Sector Underperform -> Sector Perform |
| 2023-10-09 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-10-09 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-10-09 | Jefferies | Downgrade | Buy -> Hold |
| 2023-10-06 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-10-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-10-06 | Stifel | Reiterate | Buy -> Buy |
| 2023-09-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-10 | Citigroup | Upgrade | Neutral -> Buy |
| 2023-08-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-08-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-08-09 | B. Riley Securities | Upgrade | Neutral -> Buy |
| 2023-08-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-07-27 | ScotiaBank | Initiate | Sector Underperform |
| 2023-07-24 | Guggenheim | Maintains | Buy -> Buy |
| 2023-07-24 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2023-07-24 | Barclays | Maintains | Overweight -> Overweight |
| 2023-07-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-06-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-05-25 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-05-25 | Barclays | Maintains | Overweight -> Overweight |
| 2023-05-11 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-05-11 | Oppenheimer | Reiterate | Perform -> Perform |
| 2023-05-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-04-27 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-01 | BMO Capital | Maintains | Market Perform |
MIRATI THERAPEUTICS INC / MRTX FAQ
What is the price target for MRTX stock?
22 analysts have analysed MRTX and the average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7.
What is the consensus rating for MIRATI THERAPEUTICS INC (MRTX) stock?
The consensus rating for MIRATI THERAPEUTICS INC (MRTX) is 69.0909 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
What is the number of analysts for MRTX stock?
The number of analysts covering MIRATI THERAPEUTICS INC (MRTX) is 22.